Wauwatosa, Wisconsin, and St. Louis, MO, March 25, 2025 (GLOBE NEWSWIRE) -- Splash Clinical, the new standard in trial enrollment, and C2N Diagnostics, LLC (“C2N”), a pioneer in advanced ...

A St. Louis-based company known for its work in Alzheimer's and neurological testing can expand its footprint, thanks to a $10 million investment from several life sciences companies.

C2N Diagnostics has received a $10m strategic investment out of Samsung’s life science investment fund. The US company said the cash injection would help to scale its clinical laboratory ...

C2N Diagnostics, LLC (“C2N”), a specialty diagnostics company with a vision to bring Clarity Through Innovation®, today announced a $10 million USD investment from Samsung C&T Corporation ...

Samsung C&T announced Thursday that its Life Science Fund, established in collaboration with Samsung Biologics, Samsung Bioepis and Samsung Venture Investment, will invest $10 million in C2N ...

The first-of-its-kind partnership combines Splash's recruitment platform with C2N's innovative blood tests to accelerate clinical research and improve patient experience. Wauwatosa, Wisconsin, and St.